USFDA issues warning letter to Cipla for Goa manufacturing facility

Drug firm Cipla Ltd said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa. The company further said that it remains committed to maintain highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2w2tozw
via IFTTT